Develop Robust In-Licensing Strategies in the Face of GI CGT Market Changes
Explore the evolving landscape of cell and gene therapies (CGTs) in gastroenterology. Key therapies include Anterogen's Cupistem and Takeda's Alofisel, the latter recently withdrawn by EMA. Understand market trends, develop licensing strategies, and identify opportunities in the CGT segment for GI diseases.
Dublin, May 30, 2025 (GLOBE NEWSWIRE) -- The "Cell & Gene Therapies in Dermatology Disorders: Therapeutic Analysis" report has been added to ResearchAndMarkets.com's offering.Currently, there are only two cell and gene therapies (CGTs) on the market across all gastroenterology (GI) indications.
Anterogen's Cupistem, indicated for the treatment of anal fistula in adult patients, was the first adipose tissue-derived mesenchymal stem cell (ASC) asset to receive approval in the GI market in Japan, 2012. This was followed by Takeda Pharmaceutical's Alofisel (darvadstrocel), which received approval from the European Medicines Agency (EMA) in 2018 and from Japan's Pharmaceuticals and Medical Devices Agency (PDMA) in 2021.
However, on December 13th, 2024, the EMA announced the withdrawal of Alofisel (darvadstrocel) from the EU market citing lack of data that demonstrated the benefit of this therapy in Crohn's fistulas.Both marketed therapies are prescribed when a patient has shown an inadequate response to at least one conventional or biologic therapy.Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the CGT in Gastrointestinal market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact Gastrointestinal disease targeting CGT therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Company Coverage:
Krystal Biotech Inc
RHEACELL GmbH
Tego Science Inc
Japan Tissue Engineering
Bio Solution International Co Ltd
Organogenesis Holdings Inc
EHL Bio Co Ltd
Castle Creek Biosciences Inc
Abeona Therapeutics Inc
Kangstem Biotech Co Ltd
Key Topics Covered: 1. Preface2. Executive Summary3. Introduction and Scope4. Current Treatment Options4.1. What is Cell & Gene Therapy?4.2. History of the Development of CGT in Dermatology Disorders4.3. Marketed Product Profiles - Cell and Gene Therapy4.4. Challenges and Opportunities in CGT in Dermatology Disorders5. Pricing and Reimbursement Assessment5.1. High Cost of CGTs Requires Adaptation of Payment Models to Ensure Affordability and Patient Access5.2. Price of Cell Therapy6. Regulations6.1. Regulation of CGTs in the 8MM7. Future Market Assessment7.1. Top 20 Dermatology Disorders with CGT Development7.2. Top Five Dermatology Disorders with the Most CGT Pipeline Assets7.3. Top Five Dermatology Disorders Stratified by Molecule Type7.4. CGT in Dermatology Disorders - Pre-reg and Phase II/III7.5. Additional Players Expected to Join the Competition Within Five Years7.6. Industry Trends in the Application of CGTs in Dermatology Disorders7.7. Most of CGT Market Catalyst is Concentrated in 20258. Likelihood of Approval and Phase - Transition Success Rate Analysis8.1. CGT Candidates Have Higher LoA and PTSR vs. Indication Benchmarks9. Sales Forecast9.1. Sales are forecast to reach $1.5 billion by 2030For more information about this report visit https://www.researchandmarkets.com/r/ywuy2y
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
an hour ago
- Forbes
Wealth Of Japan's 50 Richest On Forbes List Rises 14% To US$228Billion
Uniqlo founder Tadashi Yanai remains at No. 1 SINGAPORE (June 3, 2025) – The collective wealth of Japan's 50 Richest on the 2025 Forbes list rose 14% to US$228 billion, helped by a stronger yen. The complete list can be found at and as well as in the June issue of Forbes Asia. Bracing for the impact of tariffs from the U.S., its biggest export market, Japan cut its economic growth estimate for this year to 0.5% from 1.1%. The benchmark Nikkei 225 index was down nearly 2% since fortunes were last measured, but a stronger yen helped boost net worths of the country's 50 richest. Overall, 37 people on the list saw an increase in their wealth. The country's richest person, Tadashi Yanai, the retailing billionaire behind the Uniqlo clothing brand, added more than $10 billion and propelled his fortune to an all-time high of $48.2 billion. Shares of his Fast Retailing were up 20% as it reported double-digit growth in both revenue and net profit for the first six months ended February. Though the company gets only 8% of its revenue from the North American market, it has cut its growth forecast in light of the tariff threat. Masayoshi Son, founder of SoftBank Group, which reported its first annual net profit in four years for the fiscal year ended March, retained the No. 2 spot with $28.2 billion. Son is making multibillion dollar investments in AI, including in the $500 billion Stargate Project, a joint venture with OpenAI, Oracle and MGX to build AI data centers in the U.S. Taking the third spot on the list is Takemitsu Takizaki, founder of sensor manufacturer Keyence, who saw his net worth fall slightly to $20.7 billion. The wealth of Nobutada Saji (No. 4), of Suntory Holdings rose to $10.5 billion, up $1.2 billion from last year. Entering the top five ranks for the first time is Yasumitsu Shigeta (No. 5), chairman of Tokyo-listed mobile phone retailer Hikari Tsushin, which also supplies electricity and gas to small and midsized businesses. Shares of the company were up 62% in the past year on higher sales and profits, boosting Shigeta's net worth to $6.9 billion from $4.2 billion last year. The biggest gainer in percentage terms is video games billionaire Kagemasa Kozuki, whose fortune doubled to $3.5 billion, and he moved up nine places to No. 17. His Konami Group, which has racked up over 850 million downloads globally for its eFootball game with Lionel Messi as one of its brand ambassadors, scored another hit selling over two million copies of horror game 'Silent Hill 2,' which was released last October. Among the nine whose fortunes fell is the Sekiya family (No. 8), as shares of their chip-equipment maker Disco tumbled nearly 40%, pulling their net worth down by $2.4 billion – nearly a third – to $5 billion. The company was impacted by concerns over tariffs and the rising yen. The three returnees this year include Shintaro Tsuji (No. 32, $1.7 billion), founder of Sanrio, the company behind the iconic Hello Kitty brand, which has regained its sheen under Tsuji's 36-year-old grandson Tomokuni. The minimum net worth to qualify for the list rose to $1.2 billion from $980 million last year. The top 10 richest in Japan are: This list was compiled using shareholding and financial information obtained from the families and individuals, stock exchanges, annual reports and analysts. The ranking lists both individual and family fortunes, including those shared among relatives. Private companies were valued based on similar companies that are publicly traded. Net worths were based on stock prices and exchange rates as of the close of markets on May 9, 2025. The list can also include foreign citizens with business, residential or other ties to the country, or citizens who don't reside in the country but have significant business or other ties to the country. For more information, visit and About Forbes Forbes champions success by celebrating those who have made it, and those who aspire to make it. Forbes convenes and curates the most influential leaders and entrepreneurs who are driving change, transforming business and making a significant impact on the world. The Forbes brand today reaches more than 140 million people worldwide through its trusted journalism, signature LIVE and Forbes Virtual events, custom marketing programs and 42 licensed local editions in 68 countries. Forbes Media's brand extensions include real estate, education and financial services license agreements. For media queries, please contact: Catherine Ong Associates Pte Ltd Catherine Ong, cell: +65 9697 0007, Email: cath@ Chenxi Wang, cell: +65 8187 3215, Email: chenxi@
Yahoo
an hour ago
- Yahoo
UK trade minister to meet USTR Greer to discuss implementing tariff deal
LONDON (Reuters) -Britain's trade minister Jonathan Reynolds will meet U.S. Trade Representative Jamieson Greer on Tuesday to discuss the implementation of a trade deal that has been complicated by the announcement of fresh U.S. tariffs on steel. Reynolds will review recently agreed deals with counterparts from the U.S. and EU, Britain's two biggest trading partners, during a three-day trip to Paris and Brussels this week. The deals struck last month are both political pacts rather than formal trade agreements, and the details of their implementation have not been set out. Starmer and U.S. President Donald Trump agreed to reduce tariffs on British imports of cars and steel to the United States, but its delayed implementation means tariffs may go up before they come down. Last week, Trump said that tariffs on imported steel would rise to 50% from 25% from Wednesday. Industry body UK Steel said it understood that British producers would likely be impacted by the change, which would be a "body blow" to the sector. A British government spokesperson said the UK was engaging with the United States on the implications of the announcement ahead of Reynolds' meeting with Greer to discuss implementation timelines of the bilateral agreement in Paris. "We recognise our relationship with G7 allies and EU counterparts must continue to evolve and deliver a better trading environment for our businesses and exporters," Reynolds said in a statement ahead of the trip. Reynolds will also meet Indian Minister of Commerce Piyush Goyal to discuss a recently negotiated Free Trade Agreement, which is still having its legal text finalised and is subject to ratification in both countries, which could take months. After meetings with G7 and OECD counterparts in Paris, Reynolds will hold talks with EU trade commissioner Maros Sefcovic. As part of efforts to reset ties without fundamentally reopening the Brexit deal, Britain and the EU have agreed to conclude talks to remove red tape on its food trade, but details of the plan have yet to be finalised. In advance of that agreement coming into force, Britain on Monday said it would scrap border checks on fruit and vegetables imported from the European Union, that had been due to be effective beginning in July.
Wall Street Journal
2 hours ago
- Wall Street Journal
JGBs Edge Lower, Tracking Declines in U.S. Treasurys
0007 GMT — JGBs edge lower in the morning Tokyo session, tracking overnight price declines in U.S. Treasurys. JGBs and Treasurys tend to move in tandem. Market participants may also be wary over the Japanese finance ministry's auction today of 2.6 trillion yen of 10-year JGBs. 'We expect lackluster results,' two members of Barclays FICC Research say in a note. Long-term supply-demand is a headwind and risk-adjusted six-month carry rolldown lacks appeal owing to high volatility, they say. The JGB 10-year yield is up 1 bp at 1.515%. (
